6 research outputs found
Cytokines in Emery-Dreifuss muscular dystrophy: Possible pathogenetic markers and targets for treatment of disease
La distrofia muscolare di Emery-Dreifuss (EDMD) è una miopatia degenerativa ereditaria caratterizzata da debolezza e atrofia dei muscoli senza coinvolgimento del sistema nervoso. Individui EDMD presentano, inoltre, cardiomiopatia con difetto di conduzione che provoca rischio di morte improvvisa. Diversi studi evidenziano un coinvolgimento di citochine in diverse distrofie muscolari causanti infiammazione cronica, riassorbimento osseo, necrosi cellulare. Abbiamo effettuato una valutazione simultanea della concentrazione di citochine, chemochine, fattori di crescita, presenti nel siero di un gruppo di 25 pazienti EDMD. L’analisi effettuata ha evidenziato un aumento di citochine quali IL-17, TGFβ2, INF-γ e del TGFβ1. Inoltre, una riduzione del fattore di crescita VEGF e della chemochina RANTES è stata rilevata nel siero dei pazienti EDMD rispetto ai pazienti controllo. Ulteriori analisi effettuate tramite saggio ELISA hanno evidenziato un aumento dei livelli di TGFβ2 e IL-6 nel terreno di coltura di fibroblasti EDMD2. Per testare l’effetto nei muscoli, di citochine alterate, abbiamo utilizzato terreno condizionante di fibroblasti EDMD per differenziare mioblasti murini C2C12. Una riduzione del grado di differenziamento è stata osservata nei mioblasti condizionati con terreno EDMD. Trattando queste cellule con anticorpi neutralizzanti contro TGFβ2 e IL-6 si è avuto un miglioramento del grado di differenziamento. In C2C12 che esprimevano la mutazione H222P del gene Lmna,non sono state osservate alterazioni di citochine e benefici di anticorpi neutralizzanti. I dati mostrano un effetto patogenetico delle citochine alterate come osservato in fibroblasti e siero di pazienti, suggerendo un effetto sul tessuto fibrotico di muscoli EDMD. Un effetto intrinseco alla mutazione della lamina A è stato rilevato sul espressione di caveolina 3 in mioblasti differenziati EDMD. I risultati si aggiungono a dati forniti sulla patogenesi dell' EDMD confermando che fattori intrinseci ed estrinseci contribuiscono alla malattia. Utilizzo di anticorpi neutralizzanti specifici contro fattori estrinseci potrebbe rappresentare un approccio terapeutico come mostrato in questo studio.Emery-Dreifuss muscular dystrophy is a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system. Moreover, EDMD patients present cardiomypathy with conduction defects causing risk of sudden death. Different studies highlighted cytokine involvement in muscular dystrophy, causing chronic inflammation, bone resorption or cellular necrosis. We carried out a simultaneous assessment of the concentration of 24 secreted molecules using a wide screening approach. We tested serum concentrations of cytokines, chemokines and growth factors in 25 EDMD patients. Analysis showed an increase of IL-17, TGFβ2, INFγ, and TGFβ1. Furthermore, decrease of VEGF and of the chemokine Rantes was observed in EDMD patients. Further analysis displayed an increase of TGFβ2 and IL-6 levels in culture medium of EDMD skin fibroblasts. To test the effect of altered cytokine levels in muscle, we used conditioned medium from EDMD fibroblasts to culture differentiating mouse myoblasts. Reduced rate of myoblast differentiation was observed in the presence of EDMD conditioning media. Moreover, neutralizing antibodies against TGFβ2 and IL-6 rescued myogenic differentiation. In C2C12 mouse myoblasts expressing the H222P Lmna mutation, we did not observe altered cytokine levels or beneficial effects of neutralizing antibodies. These results show a pathogenetic effect of the altered secretory phenotype here observed in fibroblasts and serum from EDMD patients, hinting at a major role of fibrotic tissue in muscle misfunctioning in EDMD. Furthermore, we observed an intrinsic effect of lamin A mutations on the expression of caveolin 3 in differentiating EDMD myoblasts. Our data add to the existing knowledge on the complex EDMD pathogenesis and confirm that cell intrinsic and extrinsic factors contribute to disease. Neutralization of extrinsic factors by specific antibodies, as shown in this study, may represent a possible therapeutic perspective
Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS
Defects in stress response are main determinants of cellular senescence and organism aging. In fibroblasts from patients affected by Hutchinson-Gilford progeria, a severe LMNA-linked syndrome associated with bone resorption, cardiovascular disorders, and premature aging, we found altered modulation of CDKN1A, encoding p21, upon oxidative stress induction, and accumulation of senescence markers during stress recovery. In this context, we unraveled a dynamic interaction of lamin A/C with HDAC2, an histone deacetylase that regulates CDKN1A expression. In control skin fibroblasts, lamin A/C is part of a protein complex including HDAC2 and its histone substrates; protein interaction is reduced at the onset of DNA damage response and recovered after completion of DNA repair. This interplay parallels modulation of p21 expression and global histone acetylation, and it is disrupted by LMNAmutations leading to progeroid phenotypes. In fact, HGPS cells show impaired lamin A/C-HDAC2 interplay and accumulation of p21 upon stress recovery. Collectively, these results link altered physical interaction between lamin A/C and HDAC2 to cellular and organism aging. The lamin A/C-HDAC2 complex may be a novel therapeutic target to slow down progression of progeria symptoms
Elevated TGF \u3b22 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes
Among rare diseases caused by mutations in LMNA gene, Emery-Dreifuss Muscular Dystrophy type 2 and Limb-Girdle muscular Dystrophy 1B are characterized by muscle weakness and wasting, joint contractures, cardiomyopathy with conduction system disorders. Circulating biomarkers for these pathologies have not been identified. Here, we analyzed the secretome of a cohort of patients affected by these muscular laminopathies in the attempt to identify a common signature. Multiplex cytokine assay showed that transforming growth factor beta 2 (TGF \u3b22) and interleukin 17 serum levels are consistently elevated in the vast majority of examined patients, while interleukin 6 and basic fibroblast growth factor are altered in subgroups of patients. Levels of TGF \u3b22 are also increased in fibroblast and myoblast cultures established from patient biopsies as well as in serum from mice bearing the H222P Lmna mutation causing Emery-Dreifuss Muscular Dystrophy in humans. Both patient serum and fibroblast conditioned media activated a TGF \u3b22-dependent fibrogenic program in normal human myoblasts and tenocytes and inhibited myoblast differentiation. Consistent with these results, a TGF \u3b22 neutralizing antibody avoided fibrogenic marker activation and myogenesis impairment. Cell intrinsic TGF \u3b22-dependent mechanisms were also determined in laminopathic cells, where TGF \u3b22 activated AKT/mTOR phosphorylation. These data show that TGF \u3b22 contributes to the pathogenesis of Emery-Dreifuss Muscular Dystrophy type 2 and Limb-Girdle muscular Dystrophy 1B and can be considered a potential biomarker of those diseases. Further, the evidence of TGF \u3b22 pathogenetic effects in tenocytes provides the first mechanistic insight into occurrence of joint contractures in muscular laminopathies
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning
Type-2 Familial Partial Lipodystrophy is caused by LMNA mutations. Patients gradually lose subcutaneous fat from the
limbs, while they accumulate adipose tissue in the face and neck. Several studies have demonstrated that autophagy is
involved in the regulation of adipocyte differentiation and the maintenance of the balance between white and brown
adipose tissue. We identified deregulation of autophagy in laminopathic preadipocytes before induction of
differentiation. Moreover, in differentiating white adipocyte precursors, we observed impairment of large lipid droplet
formation, altered regulation of adipose tissue genes, and expression of the brown adipose tissue marker UCP1.
Conversely, in lipodystrophic brown adipocyte precursors induced to differentiate, we noticed activation of autophagy,
formation of enlarged lipid droplets typical of white adipocytes, and dysregulation of brown adipose tissue genes. In
agreement with these in vitro results indicating conversion of FPLD2 brown preadipocytes toward the white lineage,
adipose tissue from FPLD2 patient neck, an area of brown adipogenesis, showed a white phenotype reminiscent of its
brown origin. Moreover, in vivo morpho-functional evaluation of fat depots in the neck area of three FPLD2 patients by
PET/CT analysis with cold stimulation showed the absence of brown adipose tissue activity. These findings highlight a
new pathogenetic mechanism leading to improper fat distribution in lamin A-linked lipodystrophies and show that
both impaired white adipocyte turnover and failure of adipose tissue browning contribute to disease.We thank FPLD2 patients for donating biological samples. We thank the Italian
Network for Laminopathies and the European Consortium of Lipodystrophies
(ECLip) for support and helpful discussion. We thank Aurelio Valmori for the
technical support. The studies were supported by Rizzoli Orthopedic Institute
“5 per mille” 2014 project to MC, AIProSaB project 2016 and Fondazione Del
Monte di Bologna e Ravenna grant 2015–2016 “New pharmacological
approaches in bone laminopathies based on the use of antibodies neutralizing
TGF beta 2” to GL. GL is also supported by PRIN MIUR project 2015FBNB5Y.S